AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24928632 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Story Memory Technique (memory rehabilitation protocol)
Number of subjects: 0
Study 24928632 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23226263 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hypoxic exposure (AHE) (plus exercise)
Number of subjects: 20
Study 23226263 — intervention group
Group type: COMPARATOR
Intervention: Passive hypoxic exposure (PHE)
Number of subjects: 20
Study 20846199 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating olanzapine (ODO)
Number of subjects: 149
Study 20846199 — intervention group
Group type: COMPARATOR
Intervention: Standard olanzapine tablets (SOT)
Number of subjects: 149
Study 17427827 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% HF for 30 seconds
Number of subjects: 110
Study 17427827 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mJ laser etching
Number of subjects: 110
Study 17427827 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mJ laser etching
Number of subjects: 110
Study 17427827 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mJ laser etching
Number of subjects: 110
Study 17427827 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated specimens)
Number of subjects: 110
Study 15732859 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride/sodium hexametaphosphate dentifrice
Number of subjects: 199
Study 15732859 — intervention group
Group type: COMPARATOR
Intervention: 0.30% triclosan/2.0% Gantrez copolymer dentifrice
Number of subjects: 199
Study 12199627 — intervention group
Group type: COMPARATOR
Intervention: IFL combination (fluorouracil [5‐FU], leucovorin, and irinotecan [CPT‐11, Camptosar])
Number of subjects: 0
Study 12199627 — intervention group
Group type: COMPARATOR
Intervention: IFL with bevacizumab (Avastin)
Number of subjects: 0
Study 12199627 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU and leucovorin with SU5416
Number of subjects: 0
Study 12199627 — intervention group
Group type: COMPARATOR
Intervention: SU5416 combined with IFL
Number of subjects: 0
Study 9569999 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, diclofenac, naproxen, indomethacin, and ibuprofen
Number of subjects: 0
Study 7734469 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 65
Study 7734469 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 65
Study 7734469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 3195729 — intervention group
Group type: COMPARATOR
Intervention: 3 mg EM without bupivacaine
Number of subjects: 150
Study 3195729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg EM with 0.125% bupivacaine
Number of subjects: 150
Study 3195729 — intervention group
Group type: COMPARATOR
Intervention: 5 mg EM without bupivacaine
Number of subjects: 150
Study 3195729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg EM with 0.125% bupivacaine
Number of subjects: 150
Study 30314508 — intervention group
Group type: EXPERIMENTAL
Intervention: YWF
Number of subjects: 72
Study 30314508 — intervention group
Group type: EXPERIMENTAL
Intervention: YWF + gypsum
Number of subjects: 72
Study 30314508 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 72
Study 27172582 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF)
Number of subjects: 252
Study 27172582 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 252
Study 24978955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 863
Study 24978955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study 23227695 — intervention group
Group type: EXPERIMENTAL
Intervention: Shu-needle therapy combined with ozone injection of low concentration
Number of subjects: 130
Study 23227695 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupotomy therapy combined with ozone injection of low concentration
Number of subjects: 130
Study 20977758 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 611
Study 20977758 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 611
Study 20977758 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Treatment (MT)
Number of subjects: 611
Study 19036146 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization plus sorafenib 400 mg bid
Number of subjects: 208
Study 19036146 — intervention group
Group type: COMPARATOR
Intervention: Transarterial chemoembolization plus placebo
Number of subjects: 208
Study 16096175 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT (Estalis)
Number of subjects: 202
Study 16096175 — intervention group
Group type: COMPARATOR
Intervention: Oral HRT (Kliogest)
Number of subjects: 202
Study 12171880 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 3521
Number of subjects: 31
Study 12171880 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 5132
Number of subjects: 31
Study 9189964 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% middle molecular weight hydroxyethyl starch (HES)
Number of subjects: 16
Study 9189964 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran 60 (DEX)
Number of subjects: 16
Study 1975188 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg
Number of subjects: 48
Study 1975188 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 48
Study 1975188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7018482 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 18
Study 7018482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 18
Study 7018482 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18
Study 7018482 — intervention group
Group type: COMPARATOR
Intervention: Chlorothiazide (control)
Number of subjects: 18
Study 7018482 — intervention group
Group type: EXPERIMENTAL
Intervention: All beta adrenoreceptor-blocking drugs
Number of subjects: 18
Study 31128959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Decision Aid (DA)
Number of subjects: 570
Study 31128959 — intervention group
Group type: COMPARATOR
Intervention: Non-Interactive Decision Aid (DA)
Number of subjects: 570
Study 31128959 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 570
Study 31128959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Interactive and Non-Interactive DAs
Number of subjects: 570
Study 28935463 — intervention group
Group type: EXPERIMENTAL
Intervention: Image fusion (IF) guidance in TAVI
Number of subjects: 31
Study 28935463 — intervention group
Group type: COMPARATOR
Intervention: Control group (no image fusion)
Number of subjects: 31
Study 25222574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate (100 mg/mL, 10 mL)
Number of subjects: 67
Study 25222574 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (10 mL)
Number of subjects: 67
Study 25222574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate
Number of subjects: 67
Study 24800921 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex
Number of subjects: 56
Study 24800921 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/kg sugammadex
Number of subjects: 56
Study 24800921 — intervention group
Group type: COMPARATOR
Intervention: Placebo with enoxaparin
Number of subjects: 56
Study 24800921 — intervention group
Group type: COMPARATOR
Intervention: Placebo with UFH
Number of subjects: 56
Study 22898574 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii training (Nintendo Wii Sports™ and Nintendo Wii Fit™) for 10 weeks, 2 sessions per week
Number of subjects: 40
Study 20029520 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW+GLU (6.4% glucose solution)
Number of subjects: 3
Study 20029520 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW+PLA (placebo solution)
Number of subjects: 3
Study 20029520 — intervention group
Group type: COMPARATOR
Intervention: NORM (no beverage during training)
Number of subjects: 3
Study 20029520 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 17304006 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (58.4 ± 1.3% of VO2max) for 60 minutes
Number of subjects: 15
Study 17304006 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 15
Study 15522005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment for 3 days
Number of subjects: 27
Study 15522005 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 15522005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment
Number of subjects: 27
Study 11549996 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 206
Study 11549996 — intervention group
Group type: COMPARATOR
Intervention: No amnioinfusion (control)
Number of subjects: 206
Study 10328567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diazepam (2 mg)
Number of subjects: 9
Study 10328567 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (2 mg)
Number of subjects: 9
Study 8529334 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 12
Study 8529334 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 12
Study 8529334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraxanthine (2 mg/kg)
Number of subjects: 12
Study 8529334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraxanthine (4 mg/kg)
Number of subjects: 12
Study 8529334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2366601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 0
Study 2366601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive impairment and functional impairment
Number of subjects: 0
Study 2366601 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics (whites, nonhomeowners, living alone, prior nursing home stays)
Number of subjects: 0
Study 2366601 — intervention group
Group type: COMPARATOR
Intervention: Older persons who were unmarried, had a low income, had no assets, and those on Medicaid
Number of subjects: 0
Study 637293 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vial formulation of etomidate (30 mg etomidate sulphate in 20 ml phosphate buffered solution)
Number of subjects: 209
Study 637293 — intervention group
Group type: COMPARATOR
Intervention: New formulation of etomidate (5ml ampoules containing 2% etomidate base in polyethylene glycol 1000)
Number of subjects: 209
Study 637293 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vial formulation of etomidate
Number of subjects: 209
Study 637293 — intervention group
Group type: COMPARATOR
Intervention: New formulation of etomidate
Number of subjects: 209
Study 31596411 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant stimulation therapy (auditory, tactile, visual and vestibular)
Number of subjects: 120
Study 31596411 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 28706334 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration of MDI technique (Group A)
Number of subjects: 100
Study 28706334 — intervention group
Group type: COMPARATOR
Intervention: Pictorial leaflet for MDI technique (Group B)
Number of subjects: 100
Study 26460564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (5mg days 1-2; 3mg days 3-5)
Number of subjects: 53
Study 26460564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 53
Study 26460564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24163868 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal welding (TW) tonsillectomy
Number of subjects: 60
Study 24163868 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection (CD) tonsillectomy
Number of subjects: 60
Study 20390342 — intervention group
Group type: EXPERIMENTAL
Intervention: High CTEN expression
Number of subjects: 1409
Study 20390342 — intervention group
Group type: EXPERIMENTAL
Intervention: CTEN expression
Number of subjects: 1409
Study 20390342 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CTEN expression
Number of subjects: 1409
Study 19641483 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA) supplementation
Number of subjects: 10
Study 19641483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17272285 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-led medicines management intervention
Number of subjects: 1493
Study 17272285 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 1493
Study 14757388 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine-supplemented TPN (0.40 g/kg/d)
Number of subjects: 33
Study 14757388 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 33
Study 11159245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve blocks (supraorbital and greater occipital)
Number of subjects: 20
Study 11159245 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infiltration
Number of subjects: 20
Study 11159245 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraorbital nerve blocks
Number of subjects: 20
Study 9768932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (group A; n = 14)
Number of subjects: 42
Study 9768932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (group TA; n = 14)
Number of subjects: 42
Study 9768932 — intervention group
Group type: COMPARATOR
Intervention: No antifibrinolytics (group C; n = 14)
Number of subjects: 42
Study 9058145 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 26
Study 9058145 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 26
Study 2680271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841
Study 2680271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841
Study 2680271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841
Study 2680271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841
Study 2680271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study 804952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol 200 mg thrice daily
Number of subjects: 42
Study 804952 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (Tolamolol, Propranolol, Practolol)
Number of subjects: 42
Study 804952 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg thrice daily
Number of subjects: 42
Study 804952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol and Propranolol
Number of subjects: 42
Study 804952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol (both doses)
Number of subjects: 42
Study 31464821 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training module
Number of subjects: 74
Study 31464821 — intervention group
Group type: COMPARATOR
Intervention: Active control (wait-listed)
Number of subjects: 74
Study 28202067 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to standard treatment (N=61 for each study group)
Number of subjects: 488
Study 28202067 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (N=61 for each control group)
Number of subjects: 488
Study 28202067 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to standard treatment
Number of subjects: 488
Study 28202067 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 488
Study 24959871 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic-focused biofeedback
Number of subjects: 4
Study 24959871 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic-focused biofeedback
Number of subjects: 4
Study 24308188 — intervention group
Group type: EXPERIMENTAL
Intervention: ZHUANG medicine mediated thread moxibustion (ZMMTM) combined with Sulfasalazine (SASP)
Number of subjects: 46
Study 24308188 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SASP) alone
Number of subjects: 46
Study 24308188 — intervention group
Group type: EXPERIMENTAL
Intervention: ZMMTM combined with SASP
Number of subjects: 46
Study 22119496 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus octreotide LAR
Number of subjects: 429
Study 22119496 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus octreotide LAR
Number of subjects: 429
Study 19674729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube group (Baerveldt glaucoma implant)
Number of subjects: 212
Study 19674729 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy group (mitomycin C 0.4 mg/ml for 4 minutes)
Number of subjects: 212
Study 19674729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube group
Number of subjects: 212
Study 19674729 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy group
Number of subjects: 212
Study 16781075 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (movie distraction)
Number of subjects: 136
Study 16781075 — intervention group
Group type: COMPARATOR
Intervention: Typical Care
Number of subjects: 136
Study 15275839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius recession
Number of subjects: 0
Study 15275839 — intervention group
Group type: COMPARATOR
Intervention: No intervention (static contractures)
Number of subjects: 0
Study 11737561 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (5 sessions of 1 minute per day for 6 weeks)
Number of subjects: 28
Study 11737561 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercise)
Number of subjects: 28
Study 11737561 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 28
Study 9426083 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 6, 12 and 24 microg
Number of subjects: 28
Study 9426083 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 28
Study 7509509 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 anti-factor Xa units of Orgaran given subcutaneously twice-daily
Number of subjects: 513
Study 7509509 — intervention group
Group type: COMPARATOR
Intervention: 5,000 units standard heparin given twice-daily
Number of subjects: 513
Study 3207328 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 12 G latex rubber balloon catheter
Number of subjects: 50
Study 3207328 — intervention group
Group type: COMPARATOR
Intervention: PVC catheter of similar calibre
Number of subjects: 50
Study 29607580 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal perineal massage (APM)
Number of subjects: 108
Study 28538393 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraluminal use of Uniblocker (E group, n=20)
Number of subjects: 40
Study 28538393 — intervention group
Group type: COMPARATOR
Intervention: Intraluminal use of Uniblocker (I group, n=20)
Number of subjects: 40
Study 26181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride, calcium gluconate, sodium bicarbonate, and regular insulin with dextrose (analyzed as one drug) prepared in various sequences.
Number of subjects: 24
Study 26181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with dextrose
Number of subjects: 24
Study 26181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium salts (sodium bicarbonate, calcium chloride, calcium gluconate)
Number of subjects: 24
Study 26181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preparation
Number of subjects: 24
Study 23528523 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week course of buprenorphine-naloxone with a dose taper to zero in weeks 9-12
Number of subjects: 152
Study 23528523 — intervention group
Group type: COMPARATOR
Intervention: 2-week detoxification with buprenorphine-naloxone
Number of subjects: 152
Study 21575972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal transobturator monofilament sling with additional 2-point tape fixation
Number of subjects: 463
Study 21575972 — intervention group
Group type: COMPARATOR
Intervention: Standard transobturator intravaginal monofilament sling procedure
Number of subjects: 463
Study 21575972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal transobturator monofilament sling with additional 2-point tape fixation (in patients with intrinsic sphincter deficiency)
Number of subjects: 463
Study 21575972 — intervention group
Group type: COMPARATOR
Intervention: Standard transobturator intravaginal monofilament sling procedure (in patients with intrinsic sphincter deficiency)
Number of subjects: 463
Study 19178514 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 123
Study 19178514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous glucocorticoids
Number of subjects: 123
Study 16414445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermentable carbohydrate (FC) supplementation (40 g/d)
Number of subjects: 9
Study 14504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.3 mg
Number of subjects: 12
Study 14504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg
Number of subjects: 12
Study 14504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 12
Study 14504417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10856384 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent arteries with <50% stenosis
Number of subjects: 2119
Study 10856384 — intervention group
Group type: COMPARATOR
Intervention: Patent arteries with >=50% stenosis
Number of subjects: 2119
Study 9382012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 9382012 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0